Bile duct carcinoma
MONDO:0005496A carcinoma that arises from epithelial cells of the bile duct
Also known as: bile duct cancer, bile duct cancer (including cholangiocarcinoma), bile duct carcinoma, carcinoma of bile duct
3350 clinical trials for this condition and its sub-types, 20 tagged with Bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bile duct carcinoma
-
Extrahepatic bile duct carcinoma 51 trials · 432 incl. sub-types
6 sub-types
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
- Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types Sub-types →
- Distal biliary tract carcinoma 32 trials
- Carcinoma in situ of extrahepatic bile duct 0 trials
- Extrahepatic bile duct leiomyosarcoma 0 trials
- Extrahepatic bile duct squamous cell carcinoma 0 trials Sub-types →
-
Bile duct adenocarcinoma 17 trials · 419 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
-
Bile duct carcinoma in situ 0 trials
1 sub-type
-
Squamous cell bile duct carcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of four drugs (gemcitabine, cisplatin, quemliclustat, and zimberelimab) as a first treatment for people with advanced biliary tract cancers, including bile duct cancer. The goal is to see if this mix can slow cancer growth and help people live longe…
Phase 2 • Sponsor: Nataliya Uboha • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail shows promise in Hard-to-Treat biliary cancers
Disease control OngoingThis phase II trial tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) works better than chemotherapy alone for advanced biliary tract or gallbladder cancer. The study enrolls 57 adults who have not had prior treatment. Researc…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill targets rare bile duct cancer mutation in late-stage trial
Disease control OngoingThis study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC